GlaxoSmithKline Receives Approvable Letter For New Indications For ARIXTRA(R)(Fondaparinux Sodium) Injection PHILADELPHIA, Feb. 2 -- GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug ...
To earn CME related to this news article, click here. January 21, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the potential for ...
The FDA has asked for more information from GlaxoSmithKline regarding its application to use the anti-clotting drug Arixtra for unstable angina. GSK didn't elaborate on what the agency was looking for ...
A research report concludes that GlaxoSmithKline's anti-clotting drug Arixtra is losing ground to Rivaroxaban, made and marketed by Bayer Schering/Johnson & Johnson. Released by Decision Resources, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results